Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

This type of retinal detachment occurs as a result of abnormal inflammation or too much leakage from abnormal blood vessels.

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis ...

A synthetic molecule created in Italy has proven capable to reawakening retinal neurons to stave off degenerative illnesses of the eye, according to a new study, offering fresh hope against ...

An international team of researchers has identified new drug targets for therapies that could benefit patients with different forms of retinitis pigmentosa and other inherited retinal diseases.

Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically ... tool for genetic testing for retinal disorders and is likely to enhance ...

The restoration of differential activity is fundamental for complex retinal response to light stimulation, which allows for more natural vision." "In pre-clinical models of retinitis pigmentosa ...

In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.

Retinitis pigmentosa is a relatively rare genetic ... such as optogenetics and retinal prostheses, have led to partial results in restoring sight, above all due to the indistinct activation ...